McGill Scientist Warns Venture Capital Greed Is Blocking Life-Saving Psychiatric Drug Discovery and Innovation

McGill's Dr. Gabriella Gobbi challenges the "greedy system" of drug discovery, warning that profit motives often block affordable mental health treatments.

By: AXL Media

Published: Mar 17, 2026, 8:41 AM EDT

Source: Information for this report was sourced from Genomic Press

Profit Motives vs Medical Necessity

The current landscape of global drug development faces a systemic crisis where the advancement of medical science is frequently secondary to financial gain. Dr. Gabriella Gobbi, a Professor of Psychiatry at McGill University and a renowned senior scientist, has voiced deep concerns regarding the "greedy system" that oversees pharmaceutical innovation today. She argues that while public funding successfully sustains the initial stages of academic research, the critical and expensive transition to toxicology and first-in-human trials is controlled by private venture capital. This reliance on profit-guided investment means that treatments with low-profit margins may be abandoned regardless of their scientific merit or potential impact on patient care.

The Bedside Origin of Scientific Inquiry

The driving force behind Dr. Gobbi's research has always been the direct observation of patient struggles, a practice she refers to as moving from "bench to bedside." During her early career in Rome and later in Montreal, she recognized that clinical patterns often hold the keys to complex biological questions. Her curiosity was piqued by the observation that adolescent cannabis users frequently developed depression characterized by profound anhedonia, or the inability to feel pleasure. This clinical insight led to a rigorous research program that provided some of the first biological links between cannabinoids and serotonin systems, eventually influencing public health policy and legislation in Quebec.

Unlocking the Mysteries of Sleep and Pain

Beyond her work with cannabinoids, Dr. Gobbi has spearheaded a major research program focused on the melatonin MT2 receptor, a once-misunderstood biological target. Her laboratory was instrumental in defining where these receptors are located in the brain and elucidating their vital role in restorative NREM sleep and the management of neuropathic pain. This long-term dedication has resulted in the development of a first-in-class MT2-selective partial agonist that is currently transitioning toward clinical development. According to Dr. Gobbi, the projects that require the most time and persistence often yield the most meaningful scientific breakthroughs, highlighting the need for patience in an era of rapid-return expectations.